Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Finished Goods (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Finished Goods for 6 consecutive years, with $3.5 million as the latest value for Q3 2018.

  • Quarterly Finished Goods fell 22.92% to $3.5 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Sep 2018, down 22.92% year-over-year, with the annual reading at $5.0 million for FY2017, 42.8% up from the prior year.
  • Finished Goods for Q3 2018 was $3.5 million at Theravance Biopharma, down from $4.0 million in the prior quarter.
  • The five-year high for Finished Goods was $7.5 million in Q3 2014, with the low at $2.0 million in Q2 2017.
  • Average Finished Goods over 5 years is $4.3 million, with a median of $4.6 million recorded in 2017.
  • The sharpest move saw Finished Goods tumbled 58.75% in 2016, then skyrocketed 99.6% in 2018.
  • Over 5 years, Finished Goods stood at $5.6 million in 2014, then tumbled by 43.71% to $3.1 million in 2015, then grew by 12.44% to $3.5 million in 2016, then soared by 42.8% to $5.0 million in 2017, then tumbled by 30.29% to $3.5 million in 2018.
  • According to Business Quant data, Finished Goods over the past three periods came in at $3.5 million, $4.0 million, and $4.6 million for Q3 2018, Q2 2018, and Q1 2018 respectively.